Published: Apr 29, 2021
Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021
PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE)
Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of €980,000 from the public investment bank BPI France’s DeepTech program, for its MACA program of Macuneos (BIO201) in dry Age-Related Macular Degeneration (AMD).
The DeepTech program aims to boost highly innovative and breakthrough projects emerging from fundamental research with attractive dedicated financing tools. The funding consists of a conditional advance of €600,000 and a grant of €380,000 which wi
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos .
BIOPHYTIS SAApril 29, 2021 GMT DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential
Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021
PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of €980,000 from the public investment bank BPI France’s DeepTech program, for its MACA program of Mac
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT”
Curative Biotechnology, Inc. April 29, 2021 GMT
Kapil Bharti, Ph.D. and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board
Boca Raton, FL, April 29, 2021 (GLOBE NEWSWIRE) Curative Biotechnology, Inc. (OTC: CUBT) a development stage biomedical company focused on novel therapies for rare diseases, announced today the Company’s trading symbol change from “CTYX” to “CUBT”. As previously announced, the Company had changed its corporate name to Curative Biotechnology, Inc. to better represent its mission to discover and develop therapeutics for patients who have few, if any, effective treatments for rare diseases.
Curative Biotechnology, Inc. Announces Ticker Symbol Change to CUBT on OTC Markets
iCrowd Newswire
Company Appoints Kapil Bharti, Ph.D., and Dimiter Dimitrov, Ph.D. to Scientific and Clinical Advisory Board
Boca Raton, FL
iCrowd Newswire/ April 29, 2021 /
Curative Biotechnology, Inc. (OTC: CUBT) a development-stage biomedical company focused on novel therapies for rare diseases, announced today the Company s trading symbol change from CTYX to CUBT . As previously announced, the Company had changed its corporate name to Curative Biotechnology, Inc. to better represent its mission to discover and develop therapeutics for patients who have few, if any, effective treatments for rare diseases.